OncoNano has substantial experience with multiple payloads:

• Bi-specific and monoclonal antibodies
• Cytokines
• Fusion proteins
• Small molecules

Please contact us if there are any payloads in your pipeline that can benefit from:

• Reduced systemic toxicity
• Improved therapeutic index
• Direct payloads delivery and subsequent conditional release at the TME